. Author manuscript; available in PMC: 2015 May 1.

Published in final edited form as: Clin Gastroenterol Hepatol. 2013 Oct 23;12(5):821–827. doi: 10.1016/j.cgh.2013.10.011

Table 3.

Plasma 25(OH)D and risk of malignancy in patients with inflammatory bowel diseases, stratified by subgroups

Subgroup	Adjusted odds ratio^║^‡	95% confidence interval	p-value
By metastatic status
Non-metastatic	0.97	0.95 – 1.00	0.02
Metastatic cancer	0.98	0.96 – 1.00	0.01
Gender
Male	0.97	0.95 – 0.99	0.01
Female	0.98	0.97 – 1.00	0.03
IBD type
Crohn’s disease	0.98	0.96 – 1.00	0.02
Ulcerative colitis	0.98	0.96 – 1.00	0.02

^║

For each 1ng/mL increase in plasma 25(OH)D

^‡

Adjusted for age, gender, race, season of measurement, duration of follow up, immunosuppression use, and IBD type